指南与共识心脑血管急症消化、代谢与肾脏急症

硬化剂意外或疑似动脉内注射的管理指南

Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants.
指南 / 共识 · Phlebology · 2024-07-24
一句话结论硬化剂误入动脉应立即转至有血管/介入单元机构行DSA,大肢体缺血风险需血管内介入(血管扩张剂、抗凝、溶栓),小缺血风险推荐口服抗炎药、抗凝、血管扩张剂及抗血小板治疗。

本指南由国际多学科专家组基于文献制定共识推荐,针对超声引导或直视下硬化治疗中意外动脉内注射硬化剂这一罕见不良事件。推荐立即将实际或疑似病例转至有血管/介入单元的机构,以数字减影血管造影(DSA)确认诊断并指导动脉内治疗。大肢体缺血风险需急诊血管内干预,包括动脉内给予血管扩张剂、抗凝剂和溶栓剂,必要时机械取栓、其他血管内干预甚至开放手术;小缺血风险推荐全身口服抗炎药、抗凝药、血管扩张剂和抗血小板治疗。结论强调硬化治疗从业者须完成正规培训并熟练使用双功超声。

要点

  • 实际或疑似动脉内注射硬化剂应立即转至有血管/介入单元的机构。
  • DSA是确认诊断并帮助选择组织缺血适动脉内治疗的关键检查。
  • 大肢体缺血风险需急诊血管内干预,包括动脉内血管扩张剂、抗凝剂和溶栓剂。
  • 小缺血风险推荐全身口服抗炎药、抗凝药、血管扩张剂和抗血小板治疗。
  • 腰交感神经阻滞可考虑但出血风险高;全身抗炎、抗凝、血小板抑制和调节剂可补充血管内操作。

适用人群与场景

  • 接受超声引导或直视下硬化治疗、发生实际或疑似硬化剂动脉内注射的患者。

诊断标准与关键阈值

  • DSA是确认动脉内注射诊断并帮助选择组织缺血适动脉内治疗的关键检查。

处置流程与药物剂量

  • 实际或疑似病例应立即转至有血管/介入单元的机构。
  • 急诊血管内干预用于管理大肢体缺血风险,包括动脉内给予血管扩张剂以减少血管痉挛,以及抗凝剂和溶栓剂以减轻血栓形成。
  • 可能需要机械取栓、其他血管内干预甚至开放手术。
  • 腰交感神经阻滞可考虑,但出血风险高。
  • 全身抗炎药、抗凝药、血小板抑制剂和调节剂可补充动脉内血管内操作。
  • 小缺血风险推荐全身口服抗炎药、抗凝药、血管扩张剂和抗血小板治疗。

红旗征与不能漏的情况

  • 大肢体缺血风险需急诊血管内干预。
  • 腰交感神经阻滞出血风险高。

研究设计与关键结果

  • 国际多学科专家组代表背书学会和相关专业,审查已发表的生物医学、科学和法律文献,制定基于共识的推荐。

证据类型、等级与局限

  • 证据类型:基于共识的指南;方法:国际多学科专家组审查文献。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 硬化治疗从业者必须完成静脉和淋巴疾病(静脉学)管理的正规培训课程(专科或亚专科培训,或同等认可),并个人熟练掌握双功超声在血管(动脉和静脉)应用中的使用,以诊断并为静脉操作提供图像引导。
  • 所有进行硬化治疗的从业者必须具备动脉内注射诊断和即时管理的专业知识。

指南或共识出处

  • 指南名称:硬化剂意外或疑似动脉内注射的管理指南(Phlebology)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity.

OBJECTIVES: To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents.

METHODS: An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations.

RESULTS: Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended.

CONCLUSION: Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.

来源:Phlebology,查看原文。版权归原作者所有。

参考来源

  1. Parsi K, De Maeseneer M, van Rij AM, et al. Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants. Phlebology. 2024. PMID: 39046331. doi:10.1177/02683555241260926

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。